gemcitabine has been researched along with azomycin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y | 1 |
| Bahary, N; Borad, MJ; Chiorean, EG; Cohn, AL; Del Prete, SA; Dragovich, T; Eng, C; Kroll, S; Rarick, M; Reddy, SG; Rosen, PJ; Ryan, DP; Schelman, WR; Sigal, D; Stephenson, J; Ulrich, B; Uronis, HE | 1 |
| Ahluwalia, D; Bhupathi, D; Hart, CP; Li, W; Liu, Q; Meng, F; Ruprell, AS; Sun, JD; Wang, Y | 1 |
1 review(s) available for gemcitabine and azomycin
| Article | Year |
|---|---|
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
2 trial(s) available for gemcitabine and azomycin
| Article | Year |
|---|---|
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Proportional Hazards Models; Time Factors; Treatment Outcome; United States | 2015 |
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Xenograft Model Antitumor Assays | 2015 |
1 other study(ies) available for gemcitabine and azomycin
| Article | Year |
|---|---|
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, SCID; Nitroimidazoles; Pemetrexed; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays | 2012 |